טוען...
Irinotecan-containing doublet treatment versus irinotecan monotherapy as second-line choice for advanced gastric cancer
BACKGROUND: For patients with advanced gastric cancer (AGC), second-line chemotherapy regimen remains controversial. The efficacy and safety of irinotecan-containing doublet treatment and irinotecan monotherapy were compared in this systematic analysis. METHODS: A search was conducted on EMBASE and...
שמור ב:
| הוצא לאור ב: | BMC Gastroenterol |
|---|---|
| Main Authors: | , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BioMed Central
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5879920/ https://ncbi.nlm.nih.gov/pubmed/29609559 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12876-018-0772-4 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|